With the unraveling of the molecular basis of AML last year, new treatment options have arisen and new insights were established concerning disease response to therapy, its impact on prognosis and its relevance for post-remission treatment decisions.
The state of the art in acute myeloid leukaemia (AML) in 2016 is changing dramatically. This is the result of the availability of new techniques for genome sequencing leading to understanding of the AML ontogeny at the molecular level, redefining minimal residual disease status in daily practice, the optimised use of induction and post-remission strategies and the introduction of many novel agents. Hopefully this will ultimately lead to the long expected improvement in survival for our individual patients.
Top
